Skip to content

Cancer Health Center

Font Size

Stage Information About Plasma Cell Neoplasms

    No generally accepted staging system exists for monoclonal gammopathy of undetermined significance (MGUS), isolated plasmacytoma of bone, or extramedullary plasmacytoma. Of the plasma cell neoplasms, a staging system exists only for multiple myeloma.

    Multiple Myeloma

    Multiple myeloma is staged by estimating the myeloma tumor cell mass on the basis of the amount of monoclonal (or myeloma) protein (M protein) in the serum and/or urine, along with various clinical parameters, such as hemoglobin and serum calcium concentrations, the number of lytic bone lesions, and the presence or absence of renal failure. Impaired renal function worsens prognosis regardless of stage.

    The stage of the disease at presentation is a strong determinant of survival, but it has little influence on the choice of therapy since almost all patients, except for rare patients with solitary bone tumors or extramedullary plasmacytomas, have generalized disease.

    International staging system

    The International Myeloma Working Group studied 11,171 patients, of whom 2,901 received high-dose therapy and 8,270 received only standard-dose therapy.[1]

    An International Staging System was derived and is shown below in Table 2 2.[1]

    Table 2. 2. The International Staging System for Multiple Myeloma

    StageCriteriaMedian Survival (mo)
    IBeta-2-microglobulin <3.5 mg/L and albumin ≥3.5 g/dL62
    IIBeta-2-microglobulin <3.5 mg/L and albumin <3.5 g/dL or beta-2-microglobulin 3.5 mg/L to <5.5 mg/L44
    IIIBeta-2-microglobulin ≥5.5 mg/L29

    Genetic factors and risk groups

    Genetic aberrations detected by interphase fluorescence in situ hybridization (FISH) may define prognostic groups in retrospective and prospective analyses.[2,3] Short survival and shorter duration of response to therapy have been reported with t(4;14)(p16;q32), t(14; 16)(q32;q23), cytogenetic deletion of 13q-14, and deletion of 17p13 (p53 locus).[2,3,4,5,6] The question of whether the choice of therapy based on FISH analysis can influence outcome must await further study in prospective trials.

    Newer clinical investigations are stratifying patients with multiple myeloma into a so-called standard-risk group, which accounts for 75% of patients and has a median survival of 3 to 6 years, and a high-risk group, which has a median survival of less than 3 years.[2,3,4,5,6,7] (See Table 3 3 below.) This stratification, based on cytogenetic findings, has been derived from retrospective analyses and requires prospective validation.[7] Bone marrow samples are sent for cytogenetic and FISH analysis. Plasma cell leukemia has a particularly poor prognosis.[8]

      1|2

      Today on WebMD

      Colorectal cancer cells
      A common one in both men and women.
      Lung cancer xray
      See it in pictures, plus read the facts.
       
      sauteed cherry tomatoes
      Fight cancer one plate at a time.
      Ovarian cancer illustration
      Do you know the symptoms?
       
      Jennifer Goodman Linn self-portrait
      Blog
      what is your cancer risk
      HEALTH CHECK
       
      colorectal cancer treatment advances
      Video
      breast cancer overview slideshow
      SLIDESHOW
       
      prostate cancer overview
      SLIDESHOW
      lung cancer overview slideshow
      SLIDESHOW
       
      ovarian cancer overview slideshow
      SLIDESHOW
      Actor Michael Douglas
      Article